Icon (ICLR) Current Deferred Revenue (2009 - 2026)
Icon's (ICLR) quarterly Current Deferred Revenue came in at $1.6 billion in Q2 2026, up 5.86% year-over-year from $1.5 billion in Q2 2025, and up 3.6% quarter-over-quarter from $1.5 billion in Q1 2026.
Analysis
Icon (ICLR) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Current Deferred Revenue for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Current Deferred Revenue rose 5.86% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 5.86% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 5.64% from the prior year.
- Current Deferred Revenue was $1.6 billion for Q2 2026 at Icon, up from $1.5 billion in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $14.3 billion in Q3 2023 and troughed at $1.5 billion in Q4 2024.
- A 5-year average of $5.6 billion and a median of $1.6 billion in 2024 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue jumped 110.61% in 2022 and tumbled 88.91% in 2024, its largest moves.
- Over 5 years, Current Deferred Revenue stood at $1.5 billion in 2022, then grew by 3.91% to $1.6 billion in 2023, then slipped by 6.31% to $1.5 billion in 2024, then increased by 5.64% to $1.6 billion in 2025, then grew by 3.4% to $1.6 billion in 2026.
- The last three Current Deferred Revenue figures came in at $1.6 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Bn |
| Mar 31, 2026 | 1.55 Bn |
| Dec 31, 2025 | 1.55 Bn |
| Sep 30, 2025 | 1.53 Bn |
| Jun 30, 2025 | 1.51 Bn |
| Mar 31, 2025 | 1.50 Bn |
| Dec 31, 2024 | 1.47 Bn |
| Sep 30, 2024 | 1.59 Bn |
| Jun 30, 2024 | 1.60 Bn |
| Mar 31, 2024 | 1.71 Bn |
| Dec 31, 2023 | 1.57 Bn |
| Sep 30, 2023 | 14.30 Bn |
| Jun 30, 2023 | 13.90 Bn |
| Mar 31, 2023 | 13.80 Bn |
| Dec 31, 2022 | 1.51 Bn |
| Sep 30, 2022 | 13.50 Bn |
| Jun 30, 2022 | 13.90 Bn |
| Mar 31, 2022 | 13.60 Bn |
| Dec 31, 2021 | 1.32 Bn |
| Sep 30, 2021 | 13.00 Bn |